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A B S T R A C T
Background
Hyperthermia is a type of cancer treatment in which body tissue is exposed to high temperatures to damage and kill cancer cells. It was
introduced into clinical oncology practice several decades ago. Positive clinical results, mostly obtained in single institutions, resulted in
clinical implementation albeit in a limited number of cancer centres worldwide. Because large scale randomised clinical trials (RCTs) are
lacking, firm conclusions cannot be drawn regarding its definitive role as an adjunct to radiotherapy in the treatment of locally advanced
cervical carcinoma (LACC).
Objectives
To assess whether adding hyperthermia to standard radiotherapy for LACC has an impact on (1) local tumour control, (2) survival and (3)
treatment related morbidity.
Search methods
The electronic databases of the Cochrane Central Register of Controlled Trials (CENTRAL), (Issue 1, 2009) and Cochrane Gynaecological
Cancer Groups Specialised Register, MEDLINE, EMBASE, online databases for trial registration, handsearching of journals and conference
abstracts, reviews, reference lists, and contacts with experts were used to identify potentially eligible trials, published and unpublished
until January 2009.
Selection criteria
RCTs comparing radiotherapy alone (RT) versus combined hyperthermia and radiotherapy (RHT) in patients with LACC.
Data collection and analysis
Between 1987 and 2009 the results of six RCTs were published, these were used for the current analysis.
Main results
74% of patients had FIGO stage IIIB LACC. Treatment outcome was significantly better for patients receiving the combined treatment
(Figures 1 to 3). The pooled data analysis yielded a significantly higher complete response rate (relative risk (RR) 0.56; 95% confidence
interval (CI) 0.39 to 0.79; p < 0.001), a significantly reduced local recurrence rate at 3 years (hazard ratio (HR) 0.48; 95% CI 0.37 to 0.63; p
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< 0.001) and a significanly better overall survival (OS) at three years following the combined treatment with RHT(HR 0.67; 95% CI 0.45 to
0.99; p = 0.05). No significant diPerence was observed in treatment related acute (RR 0.99; 95% CI 0.30 to 3.31; p = 0.99) or late grade 3 to
4 toxicity (RR 1.01; CI 95% 0.44 to 2.30; p = 0.96) between both treatments.
Authors' conclusions
The limited number of patients available for analysis, methodological flaws and a significant over-representation of patients with FIGO
stage IIIB prohibit drawing definite conclusions regarding the impact of adding hyperthermia to standard radiotherapy. However, available
data do suggest that the addition of hyperthermia improves local tumour control and overall survival in patients with locally advanced
cervical carcinoma without aPecting treatment related grade 3 to 4 acute or late toxicity.
P L A I N   L A N G U A G E   S U M M A R Y
Combined use of hyperthermia and radiation therapy for treating locally advanced cervical carcinoma
Curative treatment for cervical carcinoma consists of complete surgical removal of the tumour or destruction of the tumour by means of
radiation. If the tumour has grown beyond the boundaries of the cervix or has reached a size greater than 4 cm in diameter it is designated
as a locally advanced cervical carcinoma. For these tumours surgery alone is considered inappropriate so radiotherapy is also given. Not
all tumours are equally sensitive to radiation. Generally speaking, the likliehood that radiation alone is able to cure the tumour decreases
with increasing tumour volume. In several clinical studies it was found that the liklehood of curing the tumour at the site of origin was
increased by adding hyperthermia to radiotherapy. Hyperthermia is a treatment which kills tumour cells by increasing the normal body
temperature (37 degrees celsius) up to around 42 to 43 degrees celcius at the area of the tumour for a one hour period. It is believed that
hyperthermia may kill tumour cells that under certain conditions are resistant to radiation or that hyperthermia can turn tumour cells
making them more sensitive to radiation. However, the results observed with this treatment are not consistent in subsequent clinical
studies. Therefore we analysed the results of all clinical studies published so far comparing the treatment results of radiotherapy alone
with those obtained with the combined treatment of radiotherapy and hyperthermia in patients with locally advanced cervical carcinoma.
The results do suggest a better outcome for patients treated with the combination of radiotherapy with hyperthermia. Thus following
treatment a complete disappearance of the tumour was observed more regularly, regrowth of the tumour at the site of origin during follow
up was observed less frequently and more patients were still alive at three years aRer treatment. Treatment related side ePects were
not increased by the addition of hyperthermia to standard radiotherapy. However, the number of patients included in the clinical studies
analysed is limited as the majority of patients had stage IIIB disease. The authors therefore conclude that hyperthermia may provide a
clinically relevant improvement in treatment outcome for patients with locally advanced cervical carcinoma, in particular patients with
stage IIIB disease. Additional clinical data are needed to warrant its use for all patients with locally advanced cervical carcinoma.
Combined use of hyperthermia and radiation therapy for treating locally advanced cervical carcinoma (Review)
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B A C K G R O U N D
Description of the condition
For many years radiotherapy alone has been the treatment of
choice in patients with LACC. Spread to the para-aortic lymph nodes
has been recognised as the single most important prognostic factor
(Fyles 1995; Stehman 1991). Nevertheless pelvic tumour control is a
pre-requisite for cure (Haie 1988; Rotman 1995). Perez et al reported
overall pelvic recurrences in 14%, 41%, 41% and 72%, whereas
distant recurrences only were found in 12%, 18%, 16% and 21% of
1499 patients with FIGO stage I, II, III and IVA disease treated with
radiotherapy (Perez 1998). Similarly, Horiot et al reported pelvic
recurrences in 6%,17%,43% and 56% of 1383 patients with stage I,
II, III and IVA, respectively, treated with radiotherapy (Horiot 1988).
Description of the intervention
Since 1987 the results of six randomised clinical trials (RCTs)
have been published concerning the combined treatment of
radiotherapy with hyperthermia (RHT) in patients with cervical
carcinoma (Chen 1997; Datta 1987; Harima 2001; Sharma 1991;
van der Zee 2000; Vasanthan 2005). Local tumour control and
overall survival appeared to be improved by the addition of
hyperthermia, although clinical observations were not unanimous.
Possible explanations for the discrepancy may be found in the
patient selection (e.g. with respect to stage or tumour volume )
and other confounding factors such as treatment parameters (e.g.
overall treatment time and hyperthermia technique). Therefore,
the magnitude of any beneficial ePect as well as the proper
selection of patients for any combined treatment remains to be
demonstrated.
How the intervention might work
In LACC the pelvis is the most common site of failure aRer
treatment with radiotherapy. Several tumour characteristics have
been related to the risk of pelvic failure following radiotherapy
(Eifel 1994; Fyles 1995; Haensgen 2001; Hockel 1993; Horiot 1988;
Lanciano 1991; Mendenhall 1984; Perez 1998; Stehman 1991;
Stehman 1994; Thomas 2001; Tsang 1995; Werner 1995; West
1995). Probably the single most important of these is tumour
volume (Fyles 1995; Perez 1998; Tsang 1995). Although tumour
hypoxia is suggested to be an independent prognostic factor
by some (Hockel 1999; Vaupel 2001) both animal (De Jaeger
1998; Khalil 1995; Milross 1997) and human data (Fyles 1998)
have demonstrated an association between tumour volume and
tumour hypoxia. Thus with increasing tumour volume, tumour
necrosis increases and as a result oxygenation status worsens
(De Jaeger 1998; Khalil 1995; Milross 1997). Metabolic processes
will consequently be more anaerobic and tissue pH will decrease.
It is under these circumstances that radioresistance increases
whereas hyperthermia will be most ePective. Hyperthermia is
directly cytotoxic for cells that are less radiosensitive under
these circumstances whereas tumour oxygenation will improve by
increasing blood flow. Consequently the circumstances are then
optimal for a therapeutic gain of the combination of both treatment
modalities . In addition direct radiosensitization is another ePect of
hyperthermia.
Why it is important to do this review
The potential benefit of combining hyperthermia with radiotherapy
in cervical carcinomaswas established several decades ago (Brady
1976), but RCTs are scarce. Furthermore, the number of patients
included in the few available RCTs is small and are inconsistent
regarding the beneficial ePect of hyperthermia (Harima 2001;
van der Zee 2000; Vasanthan 2005). Of importance also are the
fundamental diPerences that exist in the heating techniques used,
thus prohibiting any firm conclusion regarding the therapeutic
benefit. The majority of published data deal with technical
developments and do not provide treatment results. Despite these
drawbacks, however, overall clinical data on the combined use
of radiotherapy and hyperthermia suggest a therapeutic gain as
compared to single modality treatment (Dinges 1998; Harima 2001;
Hornback 1986;; van der Zee 2000; Vasanthan 2005). Therefore a
systematic analysis on this treatment modality is required.
O B J E C T I V E S
This systematic review aims to provide a comprehensive and
reliable summary of the ePect of hyperthermia on LACC when
applied concomitantly with radiotherapy. The specific aim is to
review all prospective RCTs (phase II and phase III) which compare
the ePectiveness of combined hyperthermia and radiotherapy
(RHT) with radiotherapy alone (RT) in patients treated for LACC.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs (phase II or III).
Types of participants
Patients of any age with histologically proven LACC and with a
WHO performance status 0 to 2 (WHO 1979). Cervical cancers with
a central diameter equal or larger than 4 cm and/or FIGO stage IIB
to IVA are considered locally advanced. Studies with less than 20
patients were excluded.
Types of interventions
Any regimen of radiotherapy for uterine cervical carcinoma
consisting of (generally considered) curative doses of external
beam radiotherapy (EBRT) with or without brachytherapy (BCT)
given concurrently or not with hyperthermia. Only studies which
used a minimum temperature of 40o celsius for hyperthermia
were included. In case of concomitant use of chemotherapy and
radiotherapy studies were included when hyperthermia was the
only treatment variable. In that case no further distinction was
made between diPerent chemotherapy schedules.
Studies in which it was not possible to separate data on patients
receiving combined hyperthermia plus radiotherapy (RHT) versus
radiotherapy alone (RT), even aRer contacting the authors, were
excluded.
Types of outcome measures
The following clinically relevant outcomes were studied:
• Complete tumour response (CR) at two months (that is no
evidence of disease as assessed with clinical examination and/
or any imaging technique).In cervical carcinoma a CR following
radiotherapy is predictive for a durable pelvic tumour control.
• Local tumour recurrence (LR) at three years aRer treatment
Combined use of hyperthermia and radiation therapy for treating locally advanced cervical carcinoma (Review)
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• Overall Survival (OS) at three years
• Grade 3 to 4 acute toxicity (Tox acute; i.e. treatment related
toxicity occurring during and/or lasting up to six weeks following
treatment) and grade 3 to 4 late toxicity (Tox late; i.e. treatment
related toxicity lasting or occurring more than six months aRer
treatment).
Search methods for identification of studies
Electronic searches
For this review we identified the relevant trials in any language
through electronic searches of the following databases:
• Cochrane Central Register of Controlled Trials (CENTRAL) (The
Cochrane Library Issue 1, 2009)
• Cochrane Gynaecological Cancer Groups Specialised Register
(beginning to present)
• MEDLINE (1966 to present)
• EMBASE (1974 to present)
• CINAHL (1982 to present)
Furthermore, various trial databases were searched for the
identification of recent completed and ongoing trials (metaRegister
of Controlled Trials, Cancer Research UK, Cancer.gov, The Eastern
Cooperative Oncology Group Trials Database). All studies identified
until January 2009 were included in the present study.
For search strategies used see Appendix 1, Appendix 2 and
Appendix 3
Search strategies have been developed and executed by the author
team.
Searching other resources
Handsearching was performed in the following journals;
International Journal of Radiation, Oncology, Biology and
Physics,Radiotherapy and Oncology; Journal of Clinical Oncology;
Clinical Oncology and the International Journal of Hyperthermia.
In addition, published abstracts of the ASTRO, ESTRO and ESHO
conference proceedings of the last three years were screened. We
scrutinised reference lists from identified studies and reviews for
additional studies. Colleagues, collaborators and other experts in
the field were asked to identify missing and unreported trials.
Data collection and analysis
Selection of studies
All titles and abstracts of reports identified by electronic searches
or handsearching were assessed to determine if they meet the
eligibility criteria by three independent review authors (CVZ, DDH,
LL). In a consensus meeting (DDH, GVM, JB, LL) discrepancies were
discussed. Furthermore, if necessary the full journal papers were
screened to identify study characteristics.
Data extraction and management
Two review authors (DDH, LL) screened the included studies
for methodological quality according to pre-determined criteria
(Assessment of risk of bias in included studies), the treatment
characteristics (radiotherapy, hyperthermia, chemotherapy) and
the results of outcome measures (Types of outcome measures). For
time to event (OS or local tumour recurrence) data, we extracted
the log of the hazard ratio [log(HR)] and its standard error from
trial reports; if these were not reported, we estimated them from
other reported statistics using the methods of Parmar 1998. We
abstracted site of recurrence, where possible. For dichotomous
outcomes (e.g. complete tumour response and adverse events),
we extracted the number of patients in each treatment arm
who experienced the outcome of interest and the number of
patients assessed at endpoint, in order to estimate a risk ratio. We
abstracted adverse events by grade of toxicity. The time points at
which outcomes were collected and reported were noted.
In addition, the following data were collected from the manuscript:
identifiers (authors, title of publication, journal name and citation),
tumour characteristics (recurrent, primary, inoperable, metastasis
and maximum tumour diameter), baseline characteristics of
study population (age, WHO performance status at the time of
randomisation, initial disease stage), treatment allocated and
number of patients randomised. The results and discrepancies of
the data extraction were discussed in diPerent meetings (DDH,
GVM, JB, LL). The quality of the hyperthermia treatment of the
diPerent studies was determined in a consensus meeting (CVZ,
DDH, GVM, JB, LL).
Assessment of risk of bias in included studies
The risk of bias was assessed using the tool described in the
Cochrane Handbook for Systematic Reviews of interventions
(Higgins 2008) addressing the following six domains:
Sequence generation (1), allocation concealment (2), blinding (3),
incomplete outcome data (4), selective reporting of outcomes(5)
and other potential threats to validity (6).
Measures of treatment e<ect
A weighted estimate of the typical treatment ePect across studies
was computed for the study outcomes. The risk ratio (RR) was used
as the ePect measure. For time-to-event outcomes such as survival
analysis, the HR was used as ePect measure. For these analyses,
p-values and total events were used and the randomization ratio
was 1:1 (Tierney 2007). Tierney 2004 was used to facilitate the
estimation of HRs from published summary statistics or data
extracted from Kaplan-Meier curves.
Dealing with missing data
We did not impute missing outcome data; if only imputed outcome
data were reported, we planned to contact trial authors to request
data on the outcomes only among participants who were assessed.
Assessment of heterogeneity
Chi-square heterogeneity tests were used to test for statistical
heterogeneity among trials. Since we anticipated that the trial
results were heterogeneous, all analysis were performed using a
random-ePects model.
R E S U L T S
Description of studies
See:Characteristics of Included studies;Characteristics of Excluded
studies.
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Results of the search
The process of selecting the included studies for this review is
summarized in Figure 1 . Of the 143 published abstracts that were
selected by the performed search, we excluded 117 abstracts.
The studies described in these abstracts did not evaluate the
interventions of interest (n = 2) or did not contain data of cervical
patient characteristics (n = 24). In addition, a total of 91 abstracts
were excluded due to the study characteristics presented, i.e.
no RCT (n = 52), a review (n = 26) or a phase 1-2 trial (n =
13). Of the remaining 26 abstracts the full journal papers were
screened (if available). ARer screening, 6 studies appeared to be not
randomised, 2 were editorial papers and 1 had an unclear design.
The remaining 6 diPerent trials (11 published papers: Franckena
2008; Chen 1997; Datta 1987; Harima 2000; Harima 2001; Sharma
1989; Sharma 1991; van der Zee 2000; van der Zee 2001; van der
Zee 2002; Vasanthan 2005) were of RCTs (Phase 2 or 3) reporting
radiotherapy together with a hyperthermia treatment (RHT) in
one arm and radiotherapy only in the other arm. Of notice, the
study of Chen et al included 120 patients with 4 treatment arms
of which 2 treatment arms contained concomitant chemotherapy
(Chen 1997). Since this analysis aimed to investigate the additional
ePect of hyperthermia on standard radiotherapy, we decided not
to include the patients treated with concomitant chemotherapy in
the pooled data analysis. Four ongoing studies that were identified
from abstracts of congresses, online databases for trial registration
and contact with experts (see table Characteristics of included
studies) are not included in the present analysis.
 
Figure 1.   Search Flow
 
Included studies
In 1987 Datta et al reported their results obtained in 53 patients
with squamous cell cervical carcinoma, FIGO stage IIIB (Datta 1987).
64 Patients were randomly assigned to standard treatment only or
combined treatment with local hyperthermia. Eleven patients were
either lost to follow-up or received incomplete treatment leaving
53 assessable patients (RT n = 26; RHT n = 27) ). No information
concerning actually delivered therapy was provided by the authors.
RHT yielded superior treatment results, i.e. 58% (15 out of 26)
versus 74% (20 out of 27) CR, 46% (12 out of 26) versus 67% (18 out
of 27) pelvic failure free survival and 27% (7 out of 26) versus 59%
(16 out of 27) DFS at 2 years. The authors reported no increase of
treatment related morbidity although detailed information was not
provided.
In 1991 Sharma et al reported their results obtained in 50 patients
with cervical carcinoma FIGO stage II-IIIB (Sharma 1991). FiRy
patients were randomly assigned to RT or RHT. Two patients in
each group were lost to follow-up whereas another 4 patients were
not assessable for local tumour control aRer a minimal follow-
up period of 18 months leaving 42 patients (i.e. 22 RT and 20
RHT group). No information concerning actually delivered therapy
was provided by the authors. Strictly local tumour control was
Combined use of hyperthermia and radiation therapy for treating locally advanced cervical carcinoma (Review)
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evaluated, i.e. any pelvic side wall or distant recurrence was
ignored. No details are provided on the duration of follow-up. RHT
yielded superior treatment results , i.e. 50% (11 out of 22) versus
30% (6 out of 20) LR at 18 months for patients treated with RT and
RHT, respectively. The authors reported no increase of treatment
related morbidity although detailed information was not provided
for late toxicity.
In 1997 Chen et al reported their results obtained in a study
including 120 patients with cervical carcinoma, FIGO stage IIB -
IIIB (Chen 1997). One hundred and twenty patients were randomly
assigned to 1 of 4 treatment groups, no detailed information
concerning the randomisation procedure was provided. Treatment
consisted of RT, RHT, radiotherapy combined with chemotherapy
(CRT) and radiotherapy combined with both hyperthermia and
chemotherapy (TRIPLE). Vaginal applicators were used for the
hyperthermia intervention but no further details were provided
regarding the hyperthermia technique. No information concerning
actually delivered therapy was provided by the authors. Treatment
results were not significantly diPerent , i.e. 46% (14 out of 30) versus
60% (18 out of 30) complete remission for the RT and RHT group.
The authors reported no increase of acute treatment related rectal
and bladder morbidity between the treatment groups although
detailed information about the grade of toxicity was not provided.
In 2000 van der Zee et al reported their results obtained in a
multicenter study including 114 patients with cervical carcinoma
FIGO stage IIB-IVA (van der Zee 2000). Twenty-six patients did
not complete radiotherapy treatment as planned because of
insuPicient tumour regression (n = 8 and n = 3), exceeding normal
tissue dose constraints (n = 1 and n = 2), development of metastatic
disease (n = 3 and n = 0), inability to access the cervical canal (n =
1 and n = 2), a cervical stump tumour (n = 0 and n = 2), intercurrent
death (n = 1 and n = 1) and unknown (n = 3) in the control and
experimental group, respectively. Median follow up was 43 months.
RHT yielded superior treatment results i.e. 57% (32 out of 56) versus
83% (48 out of 58) CR, 41% versus 61% pelvic failure free survival
and 27% versus 51% OS at 3 years for patients treated with RT
and RHT, respectively. No diPerence in acute and late grade 3 to 4
treatment related rectal and/or bladder morbidity was observed.
In 2001 Harima et al reported their results obtained in a study
including 40 patients with cervical carcinoma FIGO stage IIIB
(Harima 2001). Mean follow-up was 25 (3.5 to 60.1) and 36 (5.9 to
64.3) months for the RT and RHT group, respectively. RHT yielded
superior treatment results, i.e. 50% (10 out of 20) versus 80% (16 out
of 20) CR; 50% versus 20% pelvic failure rate; 45% versus 64% DFS
and 48% versus 58% OS at 3 years for patients treated with RT and
RHT, respectively. Toxicity was not significantly diPerent between
treatment groups. However, in contrast to the RT group where no
acute or late toxicity of any grade was observed, in the RHT group 1
patient had grade 3 acute bowel toxicity (RTOG score, Rubin 1995)
and 2 patients developed grade 3 late bowel toxicity (obstructive
colonic ileus and sigmoid-ileum fistula) aRer 1.5 and 2 years aRer
treatment.
In 2005 Vasanthan et al reported their results obtained in a
multicenter study in 110 patients with cervical carcinoma FIGO
stage IIB -IVA (Vasanthan 2005). Median follow-up was 15.7 months
for all patients and 17.2 months for surviving patients. Treatment
results did not diPer between RT and RHT groups. A subgroup
analysis in 56 patients with stage IIB cervical carcinoma yielded a
significantly worse survival for the RHT group whereas local control
was similar for the 2 treatment groups. No details are provided
concerning the cause of death or the location of disease recurrence.
No significant diPerence in acute or late toxicity was observed.
Grade 3 acute toxicity was observed only in 1 patient treated with
RHT (grade 3 blister). Grade 3 bowel toxicity was equally distributed
between treatment groups (n = 2 per group). One grade 4 bowel
toxicity was observed in a patient treated with RT.
Quality of treatment
Radiotherapy
In general, state of the art treatment of LACC requires adequate
EBRT combined with brachytherapy. Thus, EBRT doses between
45 to 50 Gy and cumulative doses between 70 to 90 Gy to 'Point
A' are considered standard. Reported radiation doses delivered
do not provide any information concerning the adequacy of
tumour dose delivery. Except for the Datta study (Datta 1987),
all standard radiotherapy protocols included combined treatment
with EBRT and brachytherapy. To study the beneficial ePect of
any additional intervention to standard treatment ideally requires
strictly standardized treatment protocols. Not surprisingly, taken
the life span and geographical distribution of the 6 studies
published, standard treatment varies significantly. Moreover,
except for one study (Harima 2001) EBRT was not standardized
within each study. Strictly adhering to the predefined quality
criteria would mean that only three studies using hyperthermia
treatment would qualify as adequate for review analysis. However,
standard radiotherapy in these studies varied as well and would
result in cancellation of the review. Taking this into account
we decided to accept the variation in radiation therapy and
hyperthermia techniques as well as the lack of description of the
quality criteria in the manuscripts leaving 'randomised clinical
study, including at least 20 patients' as major selection criterion. In
doing so, we do realize that any outcome based on this analysis can
only be suggestive and not conclusive.
Hyperthermia
The quality of the hyperthermia treatments is diPicult to assess
from the published information. Dose-ePect relationships have
been established for several hyperthermia dose parameters
derived from the measured temperatures and the duration of
heating, and taking into account the temperature distribution.
In clinical practice, however, the number of thermometry sites
is limited and in cervical cancer the thermometry probes are
usually placed near the centre of the tumour. The temperature
data are therefore not informative on what the hyperthermia dose
has been in the entire tumour volume (van der Zee 2008). Other
studies indicate that the applied energy distribution in the tumour
volume can be used as a quality indicator (van der Zee 2008).
The energy distribution can be estimated from the information
provided in the publications. In five studies, electromagnetic (EM)
radiation was used for heating. Chen et al used an intravaginal
applicator with an unspecified source of energy, which may have
been electromagnetic radiation as well. EM radiation was applied
radiatively or capacitively (Chen 1997). Van der Zee et al used three
diPerent radiative EM systems with similar energy depositions in
pelvis-sized phantoms (van der Zee 2000).
With EM radiation at a frequency of 70 to 120 MHz, energy input
from around the pelvis and the use of interference, the energy is
deposited widely in the pelvic region (Gellermann 2005; Sreenivasa
2003). In the other studies, capacitive heating systems were used.
Combined use of hyperthermia and radiation therapy for treating locally advanced cervical carcinoma (Review)
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With capacitive heating (8 to 27 MHz) between two large electrodes
placed opposite on the patient's skin it is also possible to get
energy deposition widely in the pelvic region, provided there is
an appropriate patient selection and treatment procedure (van
der Zee 2005). Subcutaneous fat tissue is preferentially heated
by capacitive heating and must be cooled to allow for suPicient
energy input into deeper seated tissues. Superficial skin cooling
can limit the temperature increase in subcutaneous fat to an
acceptable level to a depth of approximately 2 cm (Rhee 1991). With
thicker subcutaneous fat layers, the high temperature in the deeper
subcutaneous fat will limit the total power input. Further more,
when a smaller (intravaginal) electrode is used in combination
with one or two large external electrode(s) there will be a steep
gradient of energy deposition with the maximum around the small
electrode. The energy level normalized to maximum will fall below
25% within 1 to 2 cm from the intravaginal electrode (Hiraki
2000). With capacitive heating using an intravaginal electrode, only
the central part of the tumour can be expected to be heated to
therapeutic temperatures.
Datta 1987
Hyperthermia was given twice weekly before radiotherapy. The
total number of treatments was not reported, it could have been
12 during 6 weeks of EBRT. The duration per treatment was 15 to
20 minutes aRer reaching a temperature of approximately 42.5°C,
measured in the cervical canal. Hyperthermia was induced by a 27
MHz capacitive system with two external electrodes. The authors
do not report subcutaneous fat thickness as an eligibility criterion,
nor skin cooling, nor the applied power.
Sharma 1991
Hyperthermia was given 3 times per week for a total of 12
treatments of 45 minutes duration, before radiotherapy. A 27
MHz capacitive heating system was used with a large external
and an intravaginal electrode. Temperatures were measured by
a thermocouple attached to the intravaginal electrode. In most
patients, the intravaginal temperature was 43°C for 30 minutes.
Chen 1997
Hyperthermia was given twice weekly aRer radiotherapy for a
total of 6 treatments of 45 minutes at a temperature of 42° with
an intravaginal technique. Further details of treatment are not
reported.
van der Zee 2000
Hyperthermia was applied by three centres which all used a
radiative hyperthermia system. Hyperthermia was given once a
week aRer radiotherapy, for a total of 5 treatments of 60 minutes
aRer reaching 42°C, or maximum 90 minutes. The mean power
input and achieved intraluminal (rectal, bladder and vaginal)
temperatures were reported by the centre recruiting the most
patients and were reported separately: average 706 Watts and
40.6°C (Fatehi 2007).
Harima 2001
Hyperthermia was given once a week aRer RT, for a total 3
treatments of 60 minutes duration. Hyperthermia was induced
with the Thermotron 8 MHz capacitive system with two external
electrodes. Patients with subcutaneous fat layer of less than 4 cm
were eligible.The authors do not report to have used pre-cooling.
The applied power was 800 to1500 W. Intratumour temperature
measurements were done with 4-point thermocouple probes; an
average temperature of 40.6°C was achieved.
Vasanthan 2005
Five centres participated in this study. Hyperthermia was given
once weekly before or aRer radiotherapy, for a total of 5 treatments
of 60 minutes duration.
The description of applied heating techniques is incomplete. All
centres used a 8 MHz capacitive heating system with, probably in
the majority of patients, an intravaginal electrode (van der Zee
2005). A subcutaneous fat thickness of up to 3 cm was accepted;
pre-cooling of skin was reported by only one centre. The level of
power input was reported by only one centre: a mean of 520 W,
which is relatively low. Centrally measured average temperatures
ranged between 38.1 and 42°C.
The hyperthermia techniques using radiative electromagnetic
heating or capacitive heating with external electrodes only can be
considered adequate (Datta 1987; Harima 2001; van der Zee 2000).
In the study of Sharma et al the ePect on the central tumour was
the main endpoint, for which the used intravaginal heating can
be considered adequate (Sharma 1991). In the studies by Chen
et al and Vasanthan et al the applied intravaginal heating (in the
majority of patients) must be considered inadequate for treatment
of the advanced tumours included in their studies (Chen 1997;
Vasanthan 2005).
Excluded studies
From the retrieved studies, eight studies were excluded for this
review mainly because of the used study design (El Sharouni 1997;
Fujiwara 1987; Gupta 1999; Hasegawa 1989; Hornback 1986; Kohno
1990). One study was not assessable due to limited data (Li 1993)
and one study could not be included because the trial is still
ongoing (Prosnitz 2002).
Risk of bias in included studies
The methodological quality of the included studies is shown in
the table 'Characteristics of included studies' and is summarized in
Figure 2 and Figure 3.
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Figure 2.   Methodological quality graph: review authors' judgements about each methodological quality item
presented as percentages across all included studies.
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Figure 3.   Methodological quality summary: review authors' judgements about each methodological quality item
for each included study.
 
All six included studies reported on a randomisation process. In one
study (Chen 1997) allocation concealment might be questionable.
Although there was no blinding in any study, this is unlikely to
aPect outcome. In four studies there were no missing outcome
data (Chen 1997; Harima 2001; van der Zee 2000; Vasanthan
2005) whereas in two studies the number of missing outcome
data was limited and equally distributed between intervention
groups (Datta 1987; Sharma 1991). No other problems were
detected in any of the six studies that might have introduced
a serious risk of bias. However, several other issues have to be
considered. Of importance, uniformity in treatment was far from
optimal, both for hyperthermia and radiotherapy. For example in
hyperthermia the sequencing of radiotherapy and hyperthermia
and the interval between radiotherapy and hyperthermia diPered
between and within (Vasanthan 2005) the studies. Similarly the
radiation technique, the total radiation dose applied and overall
treatment time diPered between and within the studies (van der
Zee 2000; Vasanthan 2005). Also the time point chosen for reporting
of outcome parameters varies such that for the diPerent outcome
measures only three or four out of six studies can be used for pooled
data analysis. Finally, overall the number of patients included in




Using complete tumour response at the end of treatment as
endpoint in the pooled data analysis including 267 study patients
yields a significantly better treatment outcome following RHT (RR
0.56 (95% CI 0.39 to 0.79); p < 0.001; Figure 4; Analysis 1.1).
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Figure 4.   Forest plot of comparison: 1 RT + HT versus RT: all studies, outcome: 1.1 complete tumour response.
 
Local recurrence
Using local recurrence as endpoint in the pooled data analysis
including 264 study patients yields a significantly reduced local
recurrence rate at 3 years (HR 0.48 (95% CI 0.37 to 0.63); p < 0.001;
Figure 5; Analysis 1.2) .
 
Figure 5.   Forest plot of comparison: 1 RT + HT versus RT: all studies, outcome: 1.3 local tumour recurrence 3y_HR.
 
Overall survival
Using overall survival at three years as endpoint in the pooled data
analysis including 264 study patients yielded a significantly better
survival for the combined treatment group (RHT) (HR 0.67; 95% CI
0.45 to 0.99; p = 0.05; Figure 6; Analysis 1.3).
 
Figure 6.   Forest plot of comparison: 1 RT + HT versus RT: all studies, outcome: 1.5 overall survival_HR (2 and 3
years).
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Toxicity
Using acute toxicity as endpoint in the pooled data analysis
including 310 study patients yielded no diPerence in acute
treatment related toxicity between both treatment groups (RR 0.99
(95% CI 0.30 to 3.31); p = 0.99; Figure 7; Analysis 1.4). Similarly, the
pooled data analysis using late toxicity as endpoint including 264
study patients yielded no diPerence in late toxicity between both
treatment groups (RR 1.01 (CI 95% 0.44 to 2.30); p = 0.98.
 
Figure 7.   Forest plot of comparison: 1 RT + HT versus RT: all studies, outcome: 1.7 toxicity (acute and late).
 
D I S C U S S I O N
The results of the present analysis with respect to the endpoints
studied, i.e. complete response rate following treatment, local
recurrence, OS and treatment related toxicity grade 3 to 4 indicates
a significant improvement of local (pelvic) tumour control and
overall survival at three years following the combined treatment
modality (RHT) whereas acute and late toxicity was not significantly
diPerent between both treatment groups. In four of six studies
(Datta 1987; Harima 2001; Sharma 1991; van der Zee 2000) a
significantly improved treatment outcome was observed by adding
hyperthermia to standard radiotherapy, whereas in two studies
no significant diPerence between both treatments was observed
(Chen 1997; Vasanthan 2005).
In contrast, in one study (Vasanthan 2005) an inferior survival was
observed in a subgroup of patients with FIGO stage IIB treated
with RHT, although no further information is provided on the
cause of death, whereas local tumour control was similar for both
treatment groups. Sharma et al report on an increased rate of
distant metastases in the RHTgroup although the diPerence is
not significant and no survival data are provided (Sharma 1991).
Of interest, the patient population diPered significantly between
these studies as the percentage of patients with FIGO stage IIIB
disease varied between 38 to 77 % (Chen 1997; Vasanthan 2005) and
between 70 to 100% (Datta 1987; Harima 2001; Sharma 1991; van
der Zee 2000) in the two studies showing no diPerence and the four
studies showing a beneficial ePect of hyperthermia.
Regarding treatment related toxicity, all but one study (Chen
1997) did report treatment related toxicity. Two studies (Datta
1987; Sharma 1991) found no ePect on normal tissue toxicity,
although no further details were provided. Two trials (van der Zee
2000;Vasanthan 2005) reported no increased toxicity of any kind.
One trial (Harima 2001) observed an increased late bowel toxicity
in 2 out of 20 patients treated with RHT as compared to 0 out of 20
patients treated with RT.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Taken the limited number of patients available for this analysis,
the over-representation of FIGO stage IIIB disease and the
methodological flaws as discussed, it is not possible to draw
definite conclusions regarding the beneficial ePect of hyperthermia
added to standard radiotherapy. Treatment related severe toxicity,
i.e. grade 3 to 4 seems not to be aPected by the addition of
hyperthermia to standard radiotherapy treatment. However, the
available data do suggest that superior local tumour control
rates and overall survival can be achieved in patients with LACC
by adding hyperthermia to standard radiotherapy. Although the
available data mainly apply for patients presenting with FIGO
stage IIIB disease, radiobiological considerations suggest a possible
benefit for its use in other locally advanced stages as well. Based
on the results of several recent RCTs investigating the role of
adding chemotherapy to radiotherapy this treatment combination
is currently considered standard in LACC. Considering the results of
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this analysis and the finding that the ePect of adding chemotherapy
to radiotherapy on survival seems to decrease with increasing
tumour stage hyperthermia should be considered as an alternative
in case chemotherapy is contra-indicated, especially in higher
tumour stages.
Implications for research
Taken the therapeutic benefit obtained, that is almost doubling
of a durable local control with an associated increase in overall
survival, without aPecting treatment associated toxicity and the
relatively low costs per patient, a limited number of clinical
restrictions for its application, further investigation of the role of
hyperthermia in a large scaled randomised trial is warranted. In
case of a substantiated therapeutic gain this treatment modality
should become available to all patients with this life threatening
but potentially curable disease.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Methods Single centre RCT (arms = 4 ) 
randomisation procedure: adequate, ITT: unknown, baseline characteristics similar: unknown, eligibil-
ity criteria specified: yes, losses to follow up fully accounted for: unknown, bias due withdrawal/drop-
out rate: unknown, co-interventions influenced results: no
Participants Cervical cancer patients: E: 30, C: 30. 
FIGO stage: IIB (E:7, C:7);IIIB (E:23, C: 23) 
Age: E: unknown (32-70), C: unknown (32-70) 
WHO performance:0-1
Interventions HT: Vaginal applicators. Timing: from the second week of EBRT. Duration: 45 minutes. Sequence: 1 hour
after EBRT. Frequency:twice weekly with 48 to 72 hour interval. Total number: 6. 
RT: Standard EBRT: linear accelerator or telecobalt. Two parallel opposed fields. Primary tumour and
pelvic draining lymphatics. A total dose of 20 Gy in 10 fractions in 2 weeks and an additional dose of 20
Gy in 10 fractions with a central block. 
Brachytherapy: Co-60. Timing: From the second week of EBRT. Dose per fraction: 5 to 10 Gy to 'Point A'.
Frequency: weekly. Total number: 5-6. 
CT: yes (groups were not included in analysis)
Outcomes CR (end of treatment)
Notes 2 arms (n = 60) with CT were not included in review
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk Quote: "A randomised Trial".
Allocation concealment? Unclear risk Quote: "The patients were orderly grouped according to clinical stages". Taken
the fact that it is a randomised trial this probably refers to a stratification pro-
cedure although this is not clear from the text.
Blinding? 
All outcomes





Low risk There were no missing outcome data.
Free of selective report-
ing?
Unclear risk No protocol available. An expected outcome measure was reported.
Chen 1997 
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Free of other bias? Unclear risk The study is published in a Chinese Journal. The English language used for re-
porting the material & method and result section is rather poor. Consequently




Methods Multi centre RCT (arms = 2, centre = 3 ) 
randomisation procedure: unknown, ITT:no, baseline characteristics similar: unknown, eligibility cri-
teria specified: yes, losses to follow up fully accounted for: yes, bias due with-drawal/drop-out rate: no,
co-interventions influenced results: no 
Total quality score: 2
Participants Cervical cancer patients: E: 33, C: 31. 
FIGO stage IIIB. Histology: squamous cell carcinoma: 64. 
Age: E: unknown (33-67), C: unknown (28-74) 
WHO performance:unknown
Interventions HT: Capacitative applicators consisting of 2 plates. Duration: 15-20 minutes. Sequence: immediately
preceding EBRT. Frequency: twice weekly with 72 hour interval. Total number: unknown. 
RT: Standard EBRT: telecobalt. Four field box-technique. Primary tumour and pelvic draining lymphat-
ics. Total dose of 50 to 55 Gy in 25 to 28 fractions in 5 to 5½ weeks. An additional dose to the local tu-
mour using antero-posterior opposed fields delivering a 10-15 Gy in 5-8 fractions in 1-1½ week. 
Brachytherapy: no 
CT: no
Outcomes CR (4 weeks after treatment) 
LR (2Y) 
DFS (2Y)
Notes No details on statistical analysis.
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk Quote: "All cases were randomised and divided into two groups".
Allocation concealment? Unclear risk Insufficiently described.
Blinding? 
All outcomes





Low risk The number of missing outcome data is equally distributed across the inter-
vention groups with similar reasons for missing.
Free of selective report-
ing?
Unclear risk No protocol available. Expected outcome measurements are reported.
Free of other bias? Unclear risk 11 patients were not included in the analysis due to 1) lost to follow-up or 2) in-
complete treatment. It is not stated how many patients per treatment group
are due to either reason. Consequently exclusions for reasons related to the in-
terventions cannot be ruled out.
Datta 1987 
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Methods single centre RCT (arms = 2) 
randomisation procedure: adequate, ITT: unknown, baseline characteristics similar: yes, eligibility cri-
teria specified: yes, losses to follow up fully accounted for: yes, bias due withdrawal/drop-out rate: no,
co-interventions influenced results: no 
Total quality score:4
Participants Cervical cancer patients: E: 20, C: 20 
FIGO stage IIIB (n=40) 
Histology: Squamous cell carcinoma (n=35); Adenocarcinoma (n=5).
Tumour diameter (mean): E 5.9 (+/- 2.2), C; 6.1 (+/- 1.8)
Age: E: 64.9 (unknown), C: 61.6 (unknown) 
WHO performance: unknown
Interventions HT: Capacitative applicators with 2 plates. Timing: after 3rd of 4th fraction of EBRT. Duration: 60 min-
utes. Sequence: within 30 minutes after EBRT. Frequency: once weekly. Total number: 3. 
RT: Standard EBRT: 6 MV linear accelerator. No details provided concerning radiation technique. Pri-
mary tumour and pelvic draining lymphatics. Total dose of 30.6 Gy in 17 fractions of 1.8 Gy, 5 times a
week, with an additional dose of 52.2 Gy to the parametria with central shielding. EBRT to primary tu-
mour and lymphatics 30.6 Gy/ 17 f, additional dose central block 52.2 Gy 
Brachytherapy: Ir-192 (High Dose Rate). Timing: unknown. Dose per fraction: 7.5 Gy to 'Point A'. Fre-
quency: once weekly during EBRT. Total number: 4. 
CT: no





TOX acute and late
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk Quote: "Randomization to treatment groups".
Allocation concealment? Low risk Quote: "Randomization was performed by a computer generated random
number list before the start of treatment".
Blinding? 
All outcomes





Low risk There were no missing outcome data.
Free of selective report-
ing?
Unclear risk No protocol available. Expected outcome measures are reported.
Free of other bias? Low risk  
Harima 2001 
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Methods single centre RCT (arms = 2 ) 
randomisation procedure: adequate, ITT: no, baseline characteristics similar: yes, eligibility criteria
specified: yes, losses to follow up fully accounted for: yes, bias due withdrawal/drop-out rate: no, 
co-interventions influenced results: no 
Total quality score: 4
Participants Cervical cancer patients: E: 25, C: 25 
FIGO stage IIA (n=3); IIB (n=4) andIIIB (n=43)
Histology: squamous cell carcinoma (n=50)
Tumour diameter: 2-4 cm (E: 7; C 6); >4 cm (E: 18; C 19)
Age: E: 50 (unknown), C: 48 (unknown) 
Karnofsky > 60
Interventions HT: Specially designed capacitative intraluminal radiofrequency heating system, consisting of a small
intravaginal applicator and a large extracorporeal electrode. Timing: from start of EBRT. Duration: 30
minutes. Sequence: within 30 minutes preceding EBRT. Frequency: on alternate days 3 times per week.
Total number: 12. 
RT: Standard EBRT: linear accelerator or telecobalt. Two parallel opposed fields. Primary tumour and
pelvic draining lymphatics. Total dose 45 Gy in 20 fractions in 4 weeks. If brachytherapy not feasible an
additional EBRT dose of 20 Gy in 10 fractions using same fields. 
Brachytherapy: if feasible. Cs-137 (Low Dose Rate). Timing: following EBRT. Dose per fraction: 35 Gy to
'Point A' . Total number: 1. 
CT: no
Outcomes LR (18 MO)
DFS (18 MO)
OS (18 MO) 
TOX acute and late
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk Quote: "The patients were randomised blindly into 2 groups of 25 each".
Allocation concealment? Low risk For randomisation the sealed envelope technique was used.
Blinding? 
All outcomes





Low risk The number of missing outcome data is equally distributed across the inter-
vention groups with similar reasons for missing.
Free of selective report-
ing?
Unclear risk No protocol available. Expected outcome measurements are reported.
Free of other bias? Low risk  
Sharma 1991 
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Methods Multi centre RCT (arms = 2, centre = 9 ) 
randomisation procedure: adequate, ITT: yes, baseline characteristics similar: yes, eligibility criteria
specified: yes, losses to follow up fully accounted for: yes, bias due withdrawal/drop-out rate: no, co-in-
terventions influenced results: no 
Total quality score: 5
Participants Cervical cancer patients: E: 58, C: 56 
FIGO stage IIB (n=22); IIIA (n=1); IIIB (n=80) and IVA (n=11).
Histology: squamous cell carcinoma (n=97); adenocarcinoma (n=11); other (n=6)
Tumour diameter: < 6cm (E 13; C 12); 6-8 cm (E 26; C 27); > 8 cm (E 19; C 13); unknown (E 0; C 4). 
Age: E: 51 (26-75), C: 50 (30-82) 
WHO performance:<2
Interventions HT: Regional (deep) hyperthermia was applied in 3 different centres using the BSD-2000 system, the 4-
waveguide applicator system and the coaxial TEM applicator, respectively. Timing: from the first week
of EBRT on. Frequency: once weekly. Duration: 60-90 minutes. Sequence: 1-4 hours after EBRT. Total
number: 0 (n=7);1-3 (n=11) and 4-6 (n=40). 
RT: Standard EBRT: linear accelerator. No details concerning radiation technique. Primary tumour and
pelvic draining lymphatics with or without the para-aortic lymph nodes. Total dose 46-50.4 Gy in 23-28
fractions. An additional dose to the pelvic sidewall was delivered in case of residual parametric tumour.
If brachytherapy was not feasible an additional dose with EBRT was delivered to the tumour region.
EBRT to primary tumour and lymphatics 46-50.4 Gy/ 23-28 f 
Brachytherapy: if feasible.(1) Ir-192 (High Dose Rate; n=38); Timing: following EBRT. Dose per fraction:
8.5 Gy to 'Point A'. Frequency: weekly. Total number: 2. (2) Cs-137 (Low Dose Rate; n=53); Timing: fol-
lowing EBRT. Dose per fraction: 20-30 Gy to 'Point A'. 
CT: no
Outcomes CR (at least 1 month after treatment)
LR (3Y)
OS (3Y) 
TOX acute and late
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk Quote: "Patients were randomly assigned treatment".
Allocation concealment? Low risk Quote: "Randomisation was done centrally by telephone and stratified by cen-
tre, tumour site and stage in variable block size".
Blinding? 
All outcomes





Low risk There were no missing outcome data.
Free of selective report-
ing?
Low risk The study protocol is available. All of the study's pre-specified outcome mea-
sures were reported.
van der Zee 2000 
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Free of other bias? Low risk  
van der Zee 2000  (Continued)
 
 
Methods Multi centre RCT (arms = 2, centre = 5 ) 
randomisation procedure: adequate, ITT: yes, baseline characteristics similar: yes, eligibility criteria
specified: yes, losses to follow up fully accounted for: yes, bias due withdrawal/drop-out rate: no 
co-interventions influenced results: no 
Total quality score: 5
Participants Cervical cancer patients: E: 55, C: 55 
Figo stage IIB (n=56); IIIA (n=9); IIIB (n=42) and IVA (n=3).
Histology: squamous cell carcinoma (n=103); adenocarcinoma (n=4); other (n=3).
Tumour volume (median): E: 60 cm3 ; C 50 cm3. 
Age: E: 45 (27-72), C: 50 (22-71) 
WHO performance:<2
Interventions HT: Capacitative applicators with 2 plates were used for generating local hyperthermia. In at least half
of the patients this was combined with an intravaginal electrode. Protocols varied per centre. Timing:
not available. Frequency: once weekly. Duration: 60 minutes. Sequence: immediately after EBRT (three
centres); immediately before EBRT (one centre) Not available (one centre). Total number: 3-6.
RT: Standard EBRT: 6-18 MV linear accelerator or telecobalt. Primary tumour and pelvic lymphatics.
(n = 54)
A total EBRT dose of 50 Gy in 2 Gy fractions in 5 weeks. Four field box technique. Two patients received
an additional EBRT dose of 20 Gy instead of brachytherapy. Brachytherapy: Low Dose Rate. Timing: fol-
lowing EBRT. Dose per fraction: 20-22 Gy to 'Point A'. Total number: 1.
(n = 28)
A total EBRT dose of 14-18 Gy in 2 Gy fractions followed by an additional dose of 24-32 Gy using central
shielding. Parallel opposed fields. Brachytherapy: High Dose Rate. Timing: unavailable. Dose per frac-
tion: 5 Gy to 'Point A'. Frequency: unknown. Total number: 10.
(n = 18)
A total EBRT dose of 50.4 Gy in 1.8 to 2 Gy fractions, in 5 to 6 weeks. Four field box technique. An addi-
tional parametrial boost of 5.4 Gy in 3 fractions with central shielding. Brachytherapy: Co-60 (High Dose
Rate). Timing: following EBRT dose of 50.4 Gy. Dose per fraction: 3 Gy to 'Point A'. Frequency: 3 times
weekly. Total number: 7-13.
(n = 9)
A total EBRT dose of 30 Gy in 2 Gy fractions, 5 times a week followed by an additional dose of 20 Gy with
central shielding. Four field box or parallel opposed fields. Brachytherapy: High Dose Rate. Timing: con-
comitantly with EBRT. Dose per fraction: 6 Gy to 'point A'.
(n = 1) EBRT to primary tumour and lymphatics 30 Gy/wk, Brachytherapy:
A total EBRT dose of 30 Gy in 2 Gy fractions. Brachytherapy: High Dose Rate. Timing: unavailable. Dose
per fraction: 6 Gy to 'point A'. Frequency: twice weekly. Total number: 4.
CT: no
Outcomes LR (3Y) 
OS (3Y)
Vasanthan 2005 
Combined use of hyperthermia and radiation therapy for treating locally advanced cervical carcinoma (Review)
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TOX acute and late
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Adequate sequence gener-
ation?
Low risk Quote: "Patients were registered and randomized".









Low risk There were no missing outcome data.
Free of selective report-
ing?
Unclear risk No protocol available. Not all expected outcome measures are reported.
Free of other bias? Unclear risk The study was terminated after including 110 patients instead of 258 patients
originally planned due to 1) the results of a preliminary analysis showing no




Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
El Sharouni 1997 no RCT
Fujiwara 1987 no RCT
Gupta 1999 no RCT
Hasegawa 1989 no RCT
Hornback 1986 no RCT
Kohno 1990 no RCT
Li 1993 not able to contact author
Prosnitz 2002 RCT, ongoing
RCT = Randomized clinical trial
 
Characteristics of ongoing studies [ordered by study ID]
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Contact information Department of Radiology, Kansai Medical University, Moriguchi, Osaka 570-8507, Japan. 
Y. Harima, principal investigator 
Email: harima@takii.kmu.ac.jp








RT + HT (Int)
Outcomes side effects
Starting date 01-11-06
Contact information Brachytherapy dept. 
N. Piotrkowicz , principal investigator 






Trial name or title Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With
Cervical Cancer
Methods  
Participants Cervical cancer (n = 400) 
Figo Stage IIB-IVA 
Prosnitz 
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Figo Stage IA, IB, or IIA with positive pelvic lymph nodes or parametria by imaging OR pathological-
ly involved at time of surgery






Contact information Dr. A.M. Westermann 
Afdeling Medische Oncologie 
Academisch Medisch Centrum AMC 
Universiteit van Amsterdam) 
Meibergdreef 9 






Notes Phase III 




Trial name or title RADCHOC
Methods  
Participants 376 cervical cancer 
figo stage IB-IIA (> similar to 4 CM and IIB-IVA)








Contact information Erasmus MC - Daniel den Hoed Cancer Center 
Cobi van der Zee, MD,PhD, Cobi van der Zee 
P.O. Box 5201, Rotterdam, The Netherlands 
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RT = radiotherapy, HT = Hyperthermia, Reg = regional, Int = interstitial, CT = , TOX acute = toxicity acute , TOX late = Toxicity late, EFS = Event
Free Survival , LRC = LocoRegional Control, OS = Overall Survival, QoL = Quality of Life, pts = patients, CisPt = cisplatin,
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   RT + HT versus RT: all studies





Statistical method Effect size
1 complete tumour response 4 267 Risk Ratio (M-H, Random, 95% CI) 0.56 [0.39, 0.79]
2 local tumour recurrence 3y_HR 3 264 Hazard Ratio (95% CI) 0.48 [0.37, 0.63]
3 overall survival_HR (2 and 3 years) 3   Hazard Ratio (95% CI) Subtotals only
3.1 overall survival 2 years (death within
2 years)
3 264 Hazard Ratio (95% CI) 0.65 [0.42, 1.00]
3.2 overall survival 3 years (death within
3 years)
3 264 Hazard Ratio (95% CI) 0.67 [0.45, 0.99]
4 toxicity (acute and late) 4   Risk Ratio (M-H, Random, 95% CI) Subtotals only
4.1 acute toxicity (< 3 months) 4 310 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.30, 3.31]
4.2 late toxicity 3 264 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.44, 2.30]
 
 
Analysis 1.1.   Comparison 1 RT + HT versus RT: all studies, Outcome 1 complete tumour response.
Study or subgroup RT+HT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Chen 1997 12/30 16/30 39.07% 0.75[0.43,1.3]
Datta 1987 7/27 11/26 19.54% 0.61[0.28,1.34]
Harima 2001 4/20 10/20 12.37% 0.4[0.15,1.07]
van der Zee 2000 10/58 24/56 29.02% 0.4[0.21,0.76]
   
Total (95% CI) 135 132 100% 0.56[0.39,0.79]
Total events: 33 ( RT+HT ), 61 ( RT )  
Heterogeneity: Tau2=0; Chi2=2.68, df=3(P=0.44); I2=0%  
Test for overall effect: Z=3.33(P=0)  
Favours RT + HT 100.1 50.2 20.5 1 Favours RT
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Analysis 1.2.   Comparison 1 RT + HT versus RT: all studies, Outcome 2 local tumour recurrence 3y_HR.
Study or subgroup RT+HT HT Hazard Ratio Weight Hazard Ratio
  n/N n/N 95% CI   95% CI
Harima 2001 4/20 10/20 61.4% 0.35[0.25,0.48]
van der Zee 2000 23/58 33/56 24.56% 0.81[0.48,1.37]
Vasanthan 2005 16/55 16/55 14.04% 0.82[0.41,1.64]
   
Total (95% CI) 133 131 100% 0.48[0.37,0.63]
Total events: 43 (RT+HT), 59 (HT)  
Heterogeneity: Tau2=0; Chi2=9.86, df=2(P=0.01); I2=79.72%  
Test for overall effect: Z=5.49(P<0.0001)  
Favours RT+HT 100.1 50.2 20.5 1 Favours RT
 
 
Analysis 1.3.   Comparison 1 RT + HT versus RT: all studies, Outcome 3 overall survival_HR (2 and 3 years).
Study or subgroup Experimental Control Hazard Ratio Weight Hazard Ratio
  n/N n/N 95% CI   95% CI
1.3.1 overall survival 2 years (death within 2 years)  
Harima 2001 4/20 9/20 15.66% 0.56[0.19,1.67]
van der Zee 2000 22/58 33/56 66.27% 0.49[0.29,0.84]
Vasanthan 2005 9/55 6/55 18.07% 1.97[0.72,5.42]
Subtotal (95% CI) 133 131 100% 0.65[0.42,1]
Total events: 35 (Experimental), 48 (Control)  
Heterogeneity: Tau2=0; Chi2=5.7, df=2(P=0.06); I2=64.94%  
Test for overall effect: Z=1.98(P=0.05)  
   
1.3.2 overall survival 3 years (death within 3 years)  
Harima 2001 6/20 10/20 16.33% 0.6[0.22,1.59]
van der Zee 2000 27/58 38/56 66.33% 0.52[0.32,0.85]
Vasanthan 2005 11/55 6/55 17.35% 1.89[0.73,4.9]
Subtotal (95% CI) 133 131 100% 0.67[0.45,0.99]
Total events: 44 (Experimental), 54 (Control)  
Heterogeneity: Tau2=0; Chi2=5.63, df=2(P=0.06); I2=64.48%  
Test for overall effect: Z=2(P=0.05)  
Test for subgroup differences: Chi2=0.01, df=1 (P=0.92), I2=0%  
Favours RT+HT 100.1 50.2 20.5 1 Favours RT
 
 
Analysis 1.4.   Comparison 1 RT + HT versus RT: all studies, Outcome 4 toxicity (acute and late).
Study or subgroup RT+HT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
1.4.1 acute toxicity (< 3 months)  
Harima 2001 1/20 0/20 14.76% 3[0.13,69.52]
Sharma 1991 2/23 2/23 41.57% 1[0.15,6.51]
van der Zee 2000 1/58 3/56 29.24% 0.32[0.03,3]
Vasanthan 2005 1/55 0/55 14.43% 3[0.12,72.08]
Subtotal (95% CI) 156 154 100% 0.99[0.3,3.31]
Total events: 5 ( RT+HT ), 5 ( RT )  
Favours RT + HT 100.1 50.2 20.5 1 Favours RT
Combined use of hyperthermia and radiation therapy for treating locally advanced cervical carcinoma (Review)









Cochrane Database of Systematic Reviews
Study or subgroup RT+HT RT Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Random, 95% CI   M-H, Random, 95% CI
Heterogeneity: Tau2=0; Chi2=1.92, df=3(P=0.59); I2=0%  
Test for overall effect: Z=0.02(P=0.99)  
   
1.4.2 late toxicity  
Harima 2001 2/20 0/20 7.64% 5[0.26,98]
van der Zee 2000 7/58 7/56 70.26% 0.97[0.36,2.58]
Vasanthan 2005 2/55 3/55 22.1% 0.67[0.12,3.84]
Subtotal (95% CI) 133 131 100% 1.01[0.44,2.3]
Total events: 11 ( RT+HT ), 10 ( RT )  
Heterogeneity: Tau2=0; Chi2=1.36, df=2(P=0.51); I2=0%  
Test for overall effect: Z=0.02(P=0.98)  
Favours RT + HT 100.1 50.2 20.5 1 Favours RT
 
 
A P P E N D I C E S
Appendix 1. MEDLINE
#1 RANDOMIZED-CONTROLLED-TRIAL in PT





#7 #1 or #2 or #3 or #4 or #5 or #6
#8 (TG=ANIMALS) not (TG=HUMAN and TG=ANIMALS)
#9 #7 not #8
#10 CLINICAL-TRIAL in PT
#11 explode CLINICAL-TRIALS/ all subheadings
#12 (clin* near trial*) in TI
#13 (clin* near trial*) in AB
#14 (singl* or doubl* or trebl* or tripl*) near (blind* or mask*)
#15 (#14 in TI) or (#14 in AB)
#16 PLACEBOS
#17 placebo* in TI
#18 placebo* in AB
#19 random* in TI
#20 random* in AB
#21 RESEARCH-DESIGN
#22 #10 or #11 or #12 or #13 or #15 or #16 or #17 or #18 or #19 or #20 or #21
#23 (TG=ANIMALS) not (TG=HUMAN and TG=ANIMALS)
#24 #22 not #23
#25 #24 not #9
#26 TG=COMPARATIVE-STUDY
#27 explode EVALUATION-STUDIES/ all subheadings
#28 FOLLOW-UP-STUDIES
#29 PROSPECTIVE-STUDIES
#30 control* or prospectiv* or volunteer*
#31 (#30 in TI) or (#30 in AB)
#32 #26 or #27 or #28 or #29 or #31
#33 (TG=ANIMALS) not (TG=HUMAN and TG=ANIMALS)
#34 #32 not #33
#35 #34 not (#9 or #25)
#36 #9 or #25 or #35
#37explode Cervical-Intraepithelial-Neoplasia (MeSH all)
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#38 explode Uterine-Cervical-Neoplasms (MeSH all)
#39 cervi*
#40 cancer or tumor or tumour or malignan* or oncol* or carcinom* or neoplas* or growth or adenom* or cyst*
#41 #39 and #40
#42 #37 or #38 or #41
#43 radiother*
#44 radiat*
#45 explode Radiotherapy (MeSH all)
#46 explode Radiotherapy-Computer-Assisted (MeSH all)
#47 #43 or #44 or #45 or #46
#48 Hyperther*
#49 explode Hyperthermia-Induced (MeSH all)
#50 #48 or #49
#51 #42 and #47 and #50
#52 #51and #36
Appendix 2. EMBASE
#34 #33 and #17
#33 #32 and #28 and #23
#32 #31 or #30 or #29
#31 explode "hyperthermic-therapy" / all SUBHEADINGS in DEM,DER,DRM,DRR
#30 explode "hyperthermia-" / all SUBHEADINGS in DEM,DER,DRM,DRR
#29 Hyperther*
#28 #24 or #25 or #26 or #27
#27 explode "computer-assisted-radiotherapy" / all SUBHEADINGS in DEM,DER,DRM,DRR
#26 explode "radiotherapy-" / all SUBHEADINGS in DEM,DER,DRM,DRR
#25 radiat*
#24 radiother*
#23 # 18 or #19 or #20 or #21 or #22
#22 (cervi*) and (cancer or tumor or tumour or malignan* or oncol* or carcinom* or neoplas* or growth or adenom* or cyst*)
#21 cancer or tumor or tumour or malignan* or oncol* or carcinom* or neoplas* or growth or adenom* or cyst*
#20 cervi*
#19 explode "uterine-cervix-tumor" / all SUBHEADINGS in DEM,DER,DRM,DRR
#18 explode "uterine-cervix-carcinoma-in-situ" / all SUBHEADINGS in DEM,DER,DRM,DRR
#17 #12 not #16
#16 #14 not #15
#15 #13 and #14
#14 (ANIMAL or NONHUMAN) in DER
#13 HUMAN in DER
#12 #9 or #10 or #11
#11 (SINGL* or DOUBL* or TREBL* or TRIPL*) near ((BLIND* or MASK*) in TI,AB)
#10 (RANDOM* or CROSS?OVER* or FACTORIAL* or PLACEBO* or VOLUNTEER*) in TI,AB
#9 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8
#8 "SINGLE-BLIND-PROCEDURE"/ all subheadings
#7 "DOUBLE-BLIND-PROCEDURE"/ all subheadings
#6 "PHASE-4-CLINICAL-TRIAL"/ all subheadings
#5 "PHASE-3-CLINICAL-TRIAL"/ all subheadings
#4 "MULTICENTER-STUDY"/ all subheadings
#3 "CONTROLLED-STUDY"/ all subheadings
#2 "RANDOMIZATION"/ all subheadings
#1 "RANDOMIZED-CONTROLLED-TRIAL"/ all subheadings
Appendix 3. CENTRAL
#1 Cervical Intraepithelial Neoplasia
#2 MeSH descriptor Uterine Cervical Neoplasms explode all trees
#3 cervi*
#4 cancer or tumor or tumour or malignan* or oncol* or carcinom* or neoplas* or growth or adenom* or cyst*
#5 (#3 AND #4)
#6 (#1 OR #2 OR #5)
#7 radiother*
#8 radiat*
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#9 MeSH descriptor Radiotherapy explode all trees
#10 MeSH descriptor Radiotherapy, Computer-Assisted explode all trees
#11 (#7 OR #8 OR #9 OR #10)
#12 Hyperther*
#13 MeSH descriptor Hyperthermia, Induced explode all trees
#14 (#12 OR #13)
#15 (#6 AND #11 AND #14)
H I S T O R Y
Protocol first published: Issue 1, 2007
Review first published: Issue 1, 2010
 
Date Event Description




C O N T R I B U T I O N S   O F   A U T H O R S
L Lutgens provided background information, methodology support and co draRed the review. M Pijls-Johannesma designed the literature
search strategy, developed methodology and co-draRed review. J van der Zee provided expertise on hyperthermia and co-draRed the
review. G van Mastrigt, D de Haas, J.Buijsen, G.Lammering, D De Ruysscher, and P Lambin co-draRed review.
D E C L A R A T I O N S   O F   I N T E R E S T
none
S O U R C E S   O F   S U P P O R T
Internal sources
• New Source of support, Not specified.
External sources
• No sources of support supplied
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
There were several discrepancies between the methods published in the protocol and those used in the actual review.
Firstly, as a consequence of limited data, sensitivity analyses and subgroup analyses could not be performed.
A second discrepancy was the presentation of the outcomes for overall survival, disease free survival and local regional tumour control.
According to the protocol this should have been in terms of 2-year and 5-year ratios, however we were only able to extract the 2-year and
3 year figures. Due to the marginal availability of data in this review, these two measures were combined into one ratio (3-year). Moreover,
due to limited reporting on disease free survival we were not able to perform analyses for this outcome.
Finally, in order to determine the risk of bias we planned to assess the quality of the included studies by the following criteria:
• Was the randomisation process adequate?
• Was there adequate allocation concealment?
• Was the analysis performed according to intention to treat?
• Were the groups similar at baseline for the most important prognostic indicators?
• Were eligibility criteria specified?
• Were losses to follow up fully accounted for?
• Was the withdrawal/drop-out rate unlikely to cause bias?
• Were co-interventions which may have influenced the results controlled for?
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However, in the present review the risk of bias was assessed using the tool described in the Cochrane Handbook for Systematic Reviews
of interventions (Higgins 2008) addressing the following 6 domains: Sequence generation (1), allocation concealment (2), blinding (3),
incomplete outcome data (4), selective reporting of outcomes (5) and other potential threats to validity (6).
See Figure 8 for list of abbreviations used throughout this review.
 
Figure 8.   Abbreviations
 
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Combined Modality Therapy  [methods];  Hyperthermia, Induced  [*methods];  Randomized Controlled Trials as Topic;  Tumor Burden; 
Uterine Cervical Neoplasms  [pathology]  [radiotherapy]  [*therapy]
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MeSH check words
Female; Humans
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